- Home
- CIK vs AGEN Comparison
CIK vs AGEN Comparison
Compare CIK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIK | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 126.2M |
| IPO Year | 1995 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CIK | AGEN |
|---|---|---|
| Price | $2.57 | $3.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 306.8K | ★ 393.6K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $2.56 | $1.38 |
| 52 Week High | $3.01 | $7.34 |
Technical Indicators
Market Signals| Indicator | CIK | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 27.85 | 60.95 |
| Support Level | N/A | $2.92 |
| Resistance Level | $3.00 | $4.66 |
| Average True Range (ATR) | 0.03 | 0.22 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 7.69 | 95.89 |
Price Performance
Historical ComparisonAbout CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).